Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 25, 2024

SELL
$41.99 - $62.38 $88,598 - $131,621
-2,110 Reduced 98.0%
43 $2,000
Q3 2023

Oct 27, 2023

BUY
$27.8 - $45.35 $59,853 - $97,638
2,153 New
2,153 $93,000
Q2 2023

Jul 18, 2023

SELL
$36.13 - $49.49 $372,211 - $509,845
-10,302 Reduced 4.42%
222,737 $8.05 Million
Q1 2023

Apr 13, 2023

SELL
$36.54 - $54.26 $191,579 - $284,485
-5,243 Reduced 2.2%
233,039 $8.66 Million
Q4 2022

Jan 23, 2023

SELL
$41.27 - $98.62 $356,448 - $851,780
-8,637 Reduced 3.5%
238,282 $0
Q3 2022

Oct 26, 2022

SELL
$59.5 - $86.7 $323,382 - $471,214
-5,435 Reduced 2.15%
246,919 $17.2 Million
Q2 2022

Jul 25, 2022

SELL
$39.16 - $88.71 $200,851 - $454,993
-5,129 Reduced 1.99%
252,354 $16.9 Million
Q1 2022

May 02, 2022

SELL
$75.82 - $150.97 $584,344 - $1.16 Million
-7,707 Reduced 2.91%
257,483 $21.2 Million
Q4 2021

Jan 28, 2022

BUY
$132.01 - $190.29 $35 Million - $50.5 Million
265,190 New
265,190 $38.9 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.